Conv. Plasma
Nigella Sativa

All remdesivir studies
Meta analysis
study COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -100% Improvement Relative Risk Ventilation -250% Remdesivir for COVID-19  Ullah et al.  LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? Retrospective 60 patients in Pakistan Higher mortality (p=0.33) and ventilation (p=0.15), not sig. Ullah et al., Int. J. Sciences, November 2020 Favors remdesivir Favors control

Efficacy of Remdesivir in Covid-19 Patients; Multicenter Study in Lahore

Ullah et al., International Journal of Sciences, doi:10.18483/ijSci.2417
Nov 2020  
  Source   PDF   All   Meta
Small late stage (hospitalized, <12 days symptoms) remdesivir study showing non-statistically significant higher mortality with treatment.
No adjustments were made for differences in the groups. Remdesivir mean age was 49 vs. control 57. Baseline oxygen requirement was 13.4 liters treatment vs. 10.8 control. Potential confounding by indication.
Gérard, Wu, Zhou show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 100% higher, RR 2.00, p = 0.33, treatment 8 of 30 (26.7%), control 4 of 30 (13.3%).
risk of mechanical ventilation, 250.0% higher, RR 3.50, p = 0.15, treatment 7 of 30 (23.3%), control 2 of 30 (6.7%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ullah et al., 29 Nov 2020, retrospective, Pakistan, peer-reviewed, 8 authors.
This PaperRemdesivirAll
Efficacy of Remdesivir in Covid-19 Patients; Multicenter Study in Lahore
Najeeb Ullah, Khurshid Ahmad Khan, Javeid Iqbal, Asim Rana, Bilal Bin Younis, Mohsin Asif, Aijaz Zeeshan Khan Chachar, Falak Shan
International Journal of Sciences, doi:10.18483/ijsci.2417
Introduction: This Pandemic of Covid-19 has shaken the world and devastating and unpredictable nature of the disease and scenario becomes worse when we see limited treatment options for this disease. Objectives: The objective of the study was to assess the efficacy of Remdesivir in patients having early phase of the disease. Methodology: Study Settings: The study was conducted in two major tertiary care hospitals, Fatima Memorial Hospital, Bahria international Hospital, Lahore. Sample size & Sampling Technique: A total of 60 patients were selected for this study who were suffering from COVID 19, out of which 30 were given Remdesivir and 30 patients were kept in control group. Participants were enrolled in the study after fulfilling inclusion and exclusion criteria. It was Probability sampling. Study design: Non-randomized control interventional study. Data Analysis: Data was analyzed with respect to demographics and clinical characteristics. Outcome was observed in terms of recovery and death. Also, the oxygen requirement and respiratory rate was measured on presentation and on 14 th day of admission. Furthermore, coexisting conditions such as diabetes, hypertension, ischemic heart disease and chronic kidney disease were also considered regarding outcome in case group and control group. Results: Mean age of the study participants was 53.2 with standard deviation (SD)±14.6 years, whereas average age of cases was 49.2±15.1 and control 57.1±13.1 years. Male were 60% of the patients and 40% were females, whereas both cases and control had 57% males. The most common co existing disease was hypertension which attributed to 53% of the total sample size followed by diabetes which was present in 47% of the study participants. 23 (38%) participants did not have any coexisting disease. The data did not show any promises with Remdesivir therapy in patients with or without ventilatory support in comparison with participants who did not receive Remdesivir.
Adamsick, Remdesivir in patients with acute or chronic kidney disease and COVID-19, Journal of the American Society of Nephrology,
Agostini, Coronavirus susceptibility to the antiviral Remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease, MBio,
Beigel, Remdesivir for the treatment of Covid-19-preliminary report, The New England journal of medicine,
Brown, Broad spectrum antiviral Remdesivir inhibits human endemic and zoonotic delta coronaviruses with a highly divergent RNA dependent RNA polymerase, Antiviral research, doi:10.1016/j.antiviral.2019
Cao, A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19, New England Journal of Medicine,
Goldman, Remdesivir for 5 or 10 days in patients with severe Covid-19, New England Journal of Medicine,
Grant, Geoghegan, Arbyn, Mohammed, Mcguinness et al., The Prevalence of Symptoms in 24,410 Adults Infected by the Novel Coronavirus (SARS-CoV-2; COVID-19): A Systematic Review and Meta-Analysis of 148 Studies from 9 Countries, doi:org/10.2139/ssrn.3582819
Helmy, Fawzy, Elaswad, Sobieh, Kenney, The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control, Journal of Clinical Medicine, doi:1225./
Madsen, Remdesivir for the Treatment of Covid-19-Final Report, The New England Journal of Medicine,
Rathore, Ghosh, Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview, Pathogens and disease,
Wang, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, The Lancet,
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop